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Summary 
Injecting human peripheral blood mononuclear cells into severe combined immunodeficient (SCID) 
mice results in long-term engraftment of human lymphocytes, of which >98% are phenotypically 
mature,  activated T cells. Here we have characterized the human T cells that populate such hu- 
PBL-SCID chimeras.  We report  that  these human  T  cells  do not  mobilize Ca  2+  after CD3 
stimulation, i.e., their T cell receptor (TCR)-mediated signal transduction is deficient. Chimera- 
derived human T cells do not secrete lymphokines or undergo blastogenesis after CD3 stimulation, 
but proliferate in response to interleukin  2 (IL-2), defining the chimera derived human T  cells 
as anergic.  Anergy was seen in both the CD4 § and the CD8 § subpopulations.  We established 
human T cell lines from chimeras. These T cells retained their anergic state for 1-2 mo in culture, 
after which they simultaneously regained the ability to mobilize Ca  2  +, secrete lymphokines, and 
to  undergo  blastogenesis  following  stimulation  via  the  TCR.  Once  regaining  proliferative 
responsiveness  to  CD3  stimulation,  these  CD4 §  T  cell  lines  displayed  anti-SCID  mouse 
reactivity and showed no specificity for recall antigens.  All CD3-responsive CD4 § T cell clones 
obtained from such lines were SCID mouse specific, recognizing native major histocompatibility 
complex class II products on the murine cells.  In contrast,  chimera-derived human  CD8 + cell 
lines and clones did not display detectable anti-mouse reactivity. The data show that the human 
T  cell system in long term hu-PBL-SCID  chimeras is nonfunctional  due to both anergy and 
the limitation of the CD4 + repertoire to xenoreactive clones. The data suggest that long-term 
hu-PBL-SCID chimerism represents an atypical graft-versus-host reaction in which the human 
effector T  cells become anergic  in the murine  environment. 
C 
onsiderable effort has been made to create animal models 
in which functions of the human immune  system can 
be studied under experimental conditions  in vivo. An im- 
portant step in this direction was the demonstration that SCID 
mice can be stably grafted with human lymphoid cells (1-4). 
Long-term chimerism was achieved in SCID mice by injec- 
tion with peripheral blood mononuclear cells (hu-PBL-SCID 
mice)  (I)  and  by  graftment  with  fetal  lymphoid  tissues 
(SCID-hu mice) (2, 3). In both models it is well established 
that human lymphocytes populate the mice in considerable 
numbers, but the biology of chimerism remains to be elu- 
cidated. 
We have been characterizing  the human immune system 
in hu-PBL-SCID mice. We (5) and others (6-11) have shown 
that  >98%  of the human cells  that  populate the chimeras 
are  T  cells  that  uniformly  express  a  mature  (CD4 +  or 
CD8 +)  and  activated/memory  (CD45R0 +,  HLA-DR +) 
phenotype. Cells freshly isolated from chimeras were found 
not to proliferate after stimulation with anti-CD3 antibody 
but to respond to IL-2. This finding provided indirect evi- 
dence that human T cells in the chimeras are nonfunctional 
and possibly anergic. Furthermore, we have shown that, when 
cultured in the presence of IL-2, the chimera-derived human 
T cells reacquired responsiveness to CD3 stimulation, at which 
time they also proliferated  to SCID stimulator  cells. 
Thus,  our  previous  findings  raised  two  questions  fun- 
damental to the understanding of hu-PBL-SCID chimerism. 
First, is there direct evidence for the anergic state of human 
T  cells in the chimeras?  Second,  does the anti-SCID  reac- 
tivity of chimera-derived human T  cell lines indicate selec- 
tion of xenoreactive T  cell specificities  in the murine host? 
Here we report on experiments  that resolve both issues. 
First, we demonstrate that, in addition to their proliferative 
unresponsiveness, chimera derived human T cells can not be 
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the unresponsiveness is manifested at the level of signal trans- 
duction;  chimera-derived  human  T  cells  do  not  mobilize 
Ca  2+ after TCR cross-linking. These data provide direct evi- 
dence for an anergic state of human T cells in hu-PBL-SCID 
chimeras. Second, we demonstrate that all functional CD4 § 
T  cell clones isolated from independent chimera-derived T 
cell  lines  were  anti-SCID  mouse-specific,  implying  that 
xenoreactivity is  the  major  stimulus  shaping  the  human, 
CD4 §  T  cell repertoire in hu-PBL-SCID  chimeras. 
Materials and Methods 
Subjects.  Donors were 12 healthy subjects  between the ages 
22-45 (11 males,  I female). Two of these donors had not been in- 
fected with EBV as judged by a lack of serum antibodies for EBV. 
Mice.  CB.17 scid/scid  (SCID) mice were bred at the Univer- 
sity of California at Los Angeles (UCLA). CB.17, BALB/c, BALB/k, 
and B10.D2 mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME). BALB/b and B10.GD mice were a gift of Dr. 
Eli Sercarz  (UCLA). 
Grafting Mice with PBL and Recovery of Human Cells from hu- 
PBL-SCID Mic~  We followed the protocol that we published pre- 
viously (5). Briefly, 20  x  106 PBL were injected intraperitoneally 
and 30-90 d later spleen,  liver, and lungs were collected.  Single 
cell suspensions  of these organs were obtained by gently teasing 
the tissue in sterile medium and passing the disrupted tissue through 
a sterile wire mesh. Cells from the peritoneal cavity were recovered 
by repeated injection and aspiration of 5 ml R,PMI  medium. 
Flow Cytometric Analysis and Antibodies.  Two-color flow cyto- 
metric analysis was performed as described previously (5). The fol- 
lowing antibodies, specific for human cell surface markers, were 
purchased from Becton Dickinson & Co. (Mountain View, CA): 
CD3 (FITC and PE); CD4 (FITC and PE); CD8 (PE); CD19 (PE); 
CD20 (PE); CD45 (FITC); and TCR,-c~//3 (FITC); and TCR-'y/r 
(FITC). Mouse isotype controls and anti-I-A  d mAb (clone MK- 
D6) were also obtained from Becton Dickinson & Co. Biotinylated 
anti-H-2K  d mAb was purchased from PharMingen  (San Diego, 
CA). PE-conjugated streptavidin was from Caltag Laboratories (San 
Francisco, CA). Murine mAbs, specific for human TCR. variable 
regions, all FITC conjugated, were purchased from T Cell Sciences, 
Inc. (Cambridge, MA). These included mAbs specific for j3V5(a), 
/3V5(b),/3V5(c), 13V8(a),/3V12(a), 13V12(a),/3V6(a), and ccV2(a). 
Ca 2§  Flux Studies.  Ca  2+  flux analysis was performed as de- 
scribed in detail elsewhere (12). Biotinylated OKT3 at 1.25/~g/ml 
was added after loading the cells with 5 mM Indo-1 solution (Mo- 
lecular Probes Inc., Eugene, OR.), and then staining them with 
CD45 FITC. After '~2.5 rain, 100 #1 of 500/zg/ml egg white avidin 
(Sigma Chemical Co., St. Louis, MO) was added to the vial. The 
reaction was measured for an additional 3-5 min. 
Proliferation Assays with T Cells Freshly  Isolated  from Chimeras.  Cells 
were plated into 96-well fiat-bottomed plates. The number of human 
cells/well was calculated in retrospect, after the percentage of human 
cells (usually 20-50%)  had been established  by FACS  |  analysis 
(Becton Dickinson & Co.). Subsequently, fresh autologous human 
APC were added,  after being irradiated  (3,000 rad)  and T  cell 
depleted by rosetting with sheep erythrocytes (T dep. PBL)  1 (13). 
Either such T dep. PBL or unseparated PBL were used for APC, 
1 Abbreviations used in this paper: PPD, purified protein derivative; T dep. 
PBL, T cell depleted by rosetting with sheep erythrocytes. 
as indicated.  Anti-CD3  mAb (Orthoclone OKT3; Ortho Phar- 
maceutical Corp., Raritan, NJ) was used at 1/~g/ml. Recombinant 
human Ib2 (a gift of Sandoz Ltd., Basel, Switzerland) was used 
at 10 ng/ml or as specified in Fig. 1. The culture medium consisted 
of DMEM with 10% FCS, 1% glutamine, 1% nonessential amino 
acids,  and 3  x  10-5  M  2-ME.  After 5 d  of culture,  1 #Ci  of 
[3H]thymidine was added to each well.  18 h later the plates were 
harvested and the incorporation of the label was counted by liquid 
scintillation. 
Generation of Human T Cell Lines from hu-PBL-SCID Mice.  We 
have established cell lines following three protocols. In all of these 
protocols, we started with a pooled single  cell suspension  from 
spleen,  lungs,  and  the  liver  of a  single  chimera  at  4  x  106 
cells/well  in a 24-well  plate suspended  in 2 ml of medium con- 
taining 10 ng/ml of rlL-2. The medium was as described for the 
proliferation assay above. This is protocol 1. In protocol 2, T dep. 
PBL (106 cells/ml) and anti-CD3 mAb (1/xg/ml) were added at 
the initiation of the culture. In protocol 3, the human cells were 
positively sorted on a FACStar Plu~|  (14) before initiation of the T 
cell lines. These purified, chimera-derived human cells were plated 
in 96-well plates at 4  x  10  s cells/well along with T dep. PBL (105 
cells/well).  IL-2 and anti-CD3 mAb were added as in protocol 2. 
In all three protocols, cells were fed weekly with fresh DMEM 
medium containing rlL-2 (10 ng/ml). After 1 mo in culture, the 
cells were restimulated according to the original protocol and main- 
tained in IL-2 for another month. This process was repeated monthly 
for long-term culture. The cells were tested every 1-2 wk for prolifer- 
ative responsiveness  to anti-CD3 mAb. Cell lines usually became 
responsive  after 1-2 mo in culture. 
Cloning of Long-Term Chimera-derived T Cell Lines.  T cell lines 
were cloned by limiting dilution (0.3 cells/well)  in the presence 
of T  dep.  PBL (2  x  104/well),  anti-CD3 mAb (1 /~g/ml),  and 
rlL-2 (10 ng/ml) in 20/~1 DMEM medium (see above) using Ter- 
asaki microtiter plates (Robbins Scientific, Mountain View, CA) (15). 
T Cell Proliferation Assay with Chimera-derived Human T Cell Lines 
or Clones.  Chimera-derived T cell lines or clones were plated at 
3  x  104 cells/well in 96-well plates along with 10  s T dep. PBL. 
Proliferative potential was assayed by stimulation with anti-CD3 
mAh (1/zg/ml), tetanus toxin, diphtheria toxin (Wyeth Laborato- 
ries, Murietta, PA) or purified protein derivative of Mycobacterium 
tuberculosis (PPD; Evans Medical,  Langhurst, UK) at 25 /zg/ml. 
Anti-mouse reactivity was tested using irradiated (3,000 tad) spleen 
cells at 2  x  105 cells/well of the mouse strains specified. After 3 d 
of culture, 1/~Ci [3H]thymidine was added and incorporation of 
label was measured as described above. 
Hemisplenectomy.  Animals  where  anesthetized  with  pento- 
barbital (UCLA, Pharmacy) 40 mg/kg i.p., 10-15 rain before sur- 
gery. Hemisplenectomy was performed as described in detail else- 
where (16). 
Determination of Cytokine Production.  Chimera-derived human 
T cells (3  x  l& cells/well)  were stimulated with anti-CD3 mAb 
(1/zg/ml) in the presence  of T  dep.  PBL (105 cells/well)  in 24- 
well plates  with 2 ml DMEM medium. Supernatants were col- 
lected 24, 48, and 72 h later and assayed for IL-2, GM-CSF,  and 
IFN-~/by lymphokine-specific ELISA as previously described (17). 
The detection limit for IL-2 is 20 pg/ml, for IFN-y is 150 pg/ml, 
and for GM-CSF is 50 pg/ml. 
Cell-mediated Cytotoxicity  Assay.  5  d  before the  actual  SlCr 
release assay, effector cells (2  x  105 cells/well)  were preactivated 
with anti-CD3 mAb (1/~g/ml) and T dep. PBL in 24-well plates, 
with 2 ml DMEM containing IL-2 at 10 ng/ml. On the day of the 
assay, the effector cells were washed and plated at 4  x  105-2.5  x 
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Figure 1.  Freshly  isolated chimera-derived human T cells proliferate 
to IL-2 but do not proliferate to CD3 stimulation; long-term T cell lines 
regain responsiveness to TCR-mediated stimulation. (.4) Proliferative re- 
sponses by cells freshly  isolated from chimeras. Single cell suspensions were 
prepared and pooled from the spleen, lungs, and liver of individual chimeras 
and the presence of human T cells (CD45 § , CD3 +) was tested by flow 
cytometry. The cell suspension shown here contained 26.8% human T 
cells and 73.2% murine (H-2K  a+) cells. (/3 and C) Proliferative response 
by chimera-derived T cell line after 24 (B) and 36 (C) d in culture. In 
B and C murine cells were undetectable (<0.1%).  The chimera-derived 
cells were assayed  in the presence of medium alone (MED), anti-CD3 mAb 
(1 #g/ml), or recombinant IL-2 (10 ng/ml).  Cultures in (A) were sup- 
plemented with irradiated, T cell-depleted PBL as a source of autologous 
human accessory  cells. In (B) and (C) irradiated, T cell-depleted PBL (open 
bars) or irradiated unseparated PBL (solid bars) were added as indicated. 
The data shown were obtained testing T cells from a single chimera. Bars 
represent SD of [3H]thymidine incorporation in triplicate cultures. These 
results are representative for 10 chimera derived cell lines that originated 
from four human donors. (D) Recombinant IL-2-induced proliferation 
was measured in cells derived from chimeras 33-3, 75-1, and 27-2 and in 
CTLL cells. The 33-3 cells were freshly isolated from chimera 33-3, con- 
tained 57% murine  (H-2K a+) cells and 43% human T cells (CD45 +  , 
CD3 +). Similarly isolated cells from uninjected SCID mice (SCID) did 
not proliferate to doses of IL-2 to which 33-3 was highly responsive. Cells 
75-1 were obtained by FACS  |  sorting for human CD4 + cells immedi- 
ately after the isolation from the chimeras and were >99% CD3 § . 33-3 
and 75-1 did not proliferate to CD3 stimulation (not shown). Cell line 
27-2, after being cultured for 161 d, contained no detectable murine cells 
and proliferated to CD3 stimulation. Cells of each type were present in 
the IL-2 assay at 2  x  10  s cells/well. (E) Bystander proliferation of CTLL 
cells to IL-2 secreted by irradiated PBL. The data on the left of the panel 
show the results of a standard proliferation assay with unirradiated PBL 
of a human donor in response to: medium, purified protein derivate of 
M. tuberculosis  (PPD), tetanus toxoid (TT), diphtheria toxin (DIPH), or 
anti-CD3  mAb. On the right of the panel, irradiated (3,000 red) PBL 
of the same donor were tested under identical conditions, except that CTLL 
cells (2  ￿  104 cells/well) were added. 2 d later, the cultures were pulsed 
with [3H]thymidine for 12 h. Recall antigens or anti-CD3 mAb did not 
induce incorporation of label above  background in irradiated PBL or CTLL 
cells when tested separately  or when the irradiated PBL were cultured with 
CTLL in the absence of additional antigen (data not shown). The results 
in E were confirmed testing PBL of two additional human donors; also, 
in those experiments, both the pattern and magnitude of CTLL-bystander 
proliferation closely reproduced the response by the unirradiated PBL. 
104 cells/well  in U-bottomed, 96-well plates. Target cells consisted 
of Con A-activated (72 h, 3 #g/ml) spleen cells of CB17 mice that 
are congenic to SCID. Alternatively, as indicated,  cell lines  A20 
and J774 (both H-2  d) were used.  On the day of assay 107 target 
cells were labeled for 1 h with 200/xCi SlCr at 37~  washed, and 
added at 104 cells/well to the effector cells. The Cr release assay 
was performed as described previously (18). 
Results and Discussion 
Chimera-derived Human T Cells Proliferate in Response to IL-2 
But Not to Anti-CD3 Stimulation.  Cells freshly isolated from 
chimeras consisted of 10-70%  CD45 +, CD3 + cells (human 
T  cells),  with  the  remaining  cells  being  H-2K  d+  (cells  of 
SCID mouse origin)  (5).  When such cell suspensions were 
challenged with anti-CD3 antibody, no proliferative response 
was induced  (data not  shown).  Since such cell suspensions 
contained  no  detectable  human  macrophages  and  usually 
<<2%  human B  cells (5,  6,  8)  the  apparent unresponsive- 
ness of the chimera-derived human T cells might have resulted 
from the absence of functional human APC. To test this pos- 
sibility, we supplemented the cultures with autologous human 
PBL.  Addition  of irradiated,  T  cell-depleted  APC did not 
render freshly isolated chimera-derived human T cells respon- 
sive to CD3 stimulation. However, the cells proliferated with 
IL-2  (Fig.  1 A). 
To characterize  these  chimera-derived  human  T  cells  in 
depth, we established a total of 42 independent chimera-derived 
human  T  cell lines,  from  six different  human  donors.  We 
systematically used three protocols for establishing  the cell 
lines to control for the possibility of in vitro selection during 
tissue culture. First, chimera-derived cells were grown on IL-2 
alone. Second, in addition to IL-2, syngeneic, irradiated, feeder 
cells and anti-CD3 mAb were added. Third, chimera-derived 
human  cells were  sorted  to remove contaminating  murine 
cells (see Materials  and Methods)  and  then  expanded with 
IL-2, anti-CD3 mAb, and syngeneic feeder cells.  Importantly, 
all three protocols resulted in human T  cell lines with iden- 
tical properties,  as  described below. 
When chimera-derived human T  cell lines were tested for 
their responsiveness to CD3 stimulation,  conflicting results 
were obtained depending upon whether T  dep. or bulk PBL 
were used  as a  source of APC.  All chimera-derived T  cell 
lines were unresponsive to CD3 stimulation when tested with 
T  cell-depleted APC but proliferated in the presence of un- 
separated PBL (Fig. 1 B). T cell lines that had been in culture 
for over 2 mo all responded to CD3  stimulation with both 
types  of APC  (Fig.  1  C). 
Since the IL-2 response in chimera-derived cells (Fig. 1 A) 
might have resulted from proliferation by contaminating mu- 
fine cells rather than by the human T  cells,  and because of 
the apparently conflicting,  APC-dependent  data with CD3 
stimulation  (Fig.  1 B),  we performed further  experiments 
to dearly establish the proliferative phenotype of the chimera- 
derived human T  cells.  Should  the chimera-derived T  cells 
be responsive to IL-2 but unresponsive to CD3 stimulation, 
this would suggest that these T cells were in an anergic state. 
First, we determined whether the IL-2 response seen with 
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or the murine cells. Cells derived from uninjected SCID mice 
did not proliferate in response to 10 ng IL-2/ml, the concen- 
tration used to test IL-2 reactivity in chimera-derived cells, 
and were barely stimulated at high  concentrations  of IL-2 
(<100 ng/ml)  (Fig.  1 D).  In contrast,  cells freshly isolated 
from chimeras (which contained human T cells and routine 
cells) as well as sorted human T cells from chimeras (which 
did not contain detectable murine cells), both of which were 
unresponsive to CD3 stimulation, proliferated vigorously to 
IL-2 (Fig.  1 D). Freshly isolated chimera-derived human T 
cells (33-3, 75-1), and long-term chimera-derived T cell lines 
showed comparable dose response characteristics  and their 
sensitivity to IL-2 was comparable to the IL-2 sensitive indi- 
cator cell line, CTLL. These data clearly show that the IL-2 
responsive population in chimera-derived cell suspensions are 
human  T  cells,  rather  than  murine  cells. 
Next, we resolved the apparently conflicting data on the 
APC  dependency  of the  CD3  responsiveness  of chimera- 
derived T  cells (Fig.  1 B). Since both, T  dep. PBL and un- 
separated PBL functioned equally well as accessory cells for 
CD3 stimulation of long-term chimera-derived T  cell lines 
(Fig.  1 C),  it was unlikely that  the lack of responsiveness 
of freshly isolated T  cells in the presence of T  cell-depleted 
APC (Fig.  1, A  and B) resulted from deficient accessory cell 
function. We therefore tested the possibility that irradiation 
did not abrogate the ability of T cells in the unseparated PBL 
population  to secrete IL-2.  In this  scenario  the highly IL- 
2-sensitive,  chimera-derived  T cells (Fig. 1 D) would proliferate 
in a bystander fashion to the IL-2 that  was released by the 
T cells in the irradiated PBL when the latter were stimulated 
by anti-CD3 mAb. We challenged irradiated PBL with anti- 
CD3 mAb and tested whether they promoted proliferation 
of the IL-2-sensitive indicator cell line CTLL (CTLL showed 
a comparable dose response characteristic to IL-2 as chimera 
derived human T cells, Fig. 1 D). Vigorous bystander prolifer- 
ation of CTLL cells was measured  (Fig.  1 E).  Beyond the 
polyclonal stimulation with the anti-CD3 mAb, even exposure 
of irradiated  PBL to recall antigens induced sufficient IL-2 
secretion to mediate CTLL-bystander proliferation.  Strikingly, 
when irradiated  PBL were challenged with the recall antigens 
tetanus toxoid, purified protein derivate of M. tuberculosis and 
diphtheria  toxin, bystander proliferation of CTLL cells ex- 
actly reproduced the pattern of proliferation to these antigens 
by the unirradiated PBL (Fig.  1 E). Hence, the proliferative 
response by the highly IL-2-sensitive chimera-derived T cells 
to anti-CD3 stimulation in the presence of unseparated PBL 
(Fig.  1 B) represents IL-2-driven bystander proliferation by 
the chimera-derived  human  T  cells rather  than  TCR trig- 
gered blastogenesis by these cells. 
Collectively, the data in Fig.  1 establish that  freshly iso- 
lated chimera-derived  T  cells  and T  cell lines cultured for 
<30 d are responsive to IL-2 but unresponsive to CD3 stim- 
ulation, i.e., they display a proliferative phenotype that is char- 
acteristic of anergic T cells (19). Additionally, these data re- 
solve a controversy in the field,  regarding the functionality 
of the chimera-derived human T cells, highlighting  the im- 
portance of using T cell-depleted irradiated APC in prolifer- 
ative assays to avoid false positive results. 
Chimera-derived  Human  T  Cells Are Deficient  in  Cytokine 
Production.  We tested whether the chimera-derived human 
T  cells also qualify as anergic cells on the basis of defective 
cytokine production  (19).  We did not detect IL-2, IFN-% 
or GM-CSF in supernatants of anti-CD3 stimulated chimera- 
derived T  cells  that  were nonproliferative  to this  stimulus 
(Table 1). This deficiency was seen both with freshly isolated 
cells and with cell lines during  the first month in culture. 
The cell lines that we tested contained considerable numbers 
(up to 80%) of CD8 § cells, in addition to CD4 § cells. Since 
"normal"  CD8 § cells also secrete IFN-'y when stimulated 
Table  1.  Freshly Isolated Chimera-derived Human  T  Cells and T  Cell Lines  That Are Nonproliferative to  CD3 Stimulation Are 
Deficient in  Cytokine  Production 
CD3 Stimulation* 
Donor  1  Donor 2 
CDHT cellsll  CDHT cells 
Cytokine  PBL  APC:  Fresh  Non prol.S  Prol.S  PBL  APC  Fresh  Non prol.  Prol 
IL-2  292  <201  <20  <20  59  799  <20  <20  <20  119 
IFN-3~  3,404  <1501  <150  <150  63_99  6,385  <150  <150  <150  3,366 
GM-CSF  142  <501  <50  <50  84  569  <50  <50  <50  131 
* Supernatants from cultures were collected 24 h after stimulation for IL-2 and 48 h for IFN-3' and GM-CSF measurements and results are expressed 
in pg/ml. 
Autologous irradiated T dep. PBL. 
Nonproliferative or proliferative to CD3 stimulation. 
U  Chimera-derived human T cells and autologous irradiated T dep. PBL. 
! Below detection limit of the ELISA. Positive results are underlined. 
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cytokine production applies to both CD4 + and CD8 + chi- 
mera-derived  human  T  cells. 
As chimera-derived T cell lines regained their proliferative 
responsiveness to CD3 stimulation,  they also started to se- 
crete IL-2,  IFN-3',  and GM-CSF (Table  1).  Production of 
IL-2, INF-% and GM-CSF was seen in purified CD4 + and 
CD8 +  cell  lines  alike,  both  of which  were  initially  un- 
responsive to CD3 stimulation (data not shown). Therefore, 
freshly isolated chimera-derived human CD4 + and CD8 + T 
cells exhibit a reversible deficiency in cytokine production, 
another  feature of anergic T  cells  (19). 
Chimera-derived Human T  Cells Are Deficient in Activation- 
dependent Ca  z+ Mobilization.  We tested whether Ca  2+ mo- 
bilization,  one of the earliest events in TCR-induced T  cell 
activation,  was operational  in  these cells.  Anti-CD3  mAb 
treatment  failed  to  induce  Ca  2+  flux  in  freshly  isolated 
chimera-derived cells  and chimera-derived T  cell lines that 
were nonproliferative to this stimulus (Fig.  2 C). Since the 
samples  tested  contained  both  human  CD4 +  and  CD8 § 
cells (Fig.  2), the inability to mobilize Ca  ~+ applies to both 
cell  types.  The  chimera-derived  human  T  cells  exhibited 
Ca  2+  flux when membrane signaling was bypassed by ion- 
omycin treatment (Fig. 2 D). During long-term culture, the 
chimera-derived  cell  lines  simultaneously  regained  Ca  2+ 
mobilization and proliferative responsiveness to anti-CD3 stim- 
ulation  (Fig.  2 E). 
As we have previously shown, the level of CD3 and TCR- 
a/t~ expression are not decreased in chimera-derived human 
T  cells (5). Therefore,  in spite of binding to the TCR, the 
anti-CD3 mAb failed to mobilize Ca  2  +, which demonstrates 
that the anergic state of chimera-derived human T cells results 
from defective signaling via the TCR. Stimulation of chimera- 
derived T cells with Ca  ~+ ionophores and PMA, agents that 
bypass the TCR.-mediated signaling pathway, did not induce 
lymphokine production (not shown). This suggests that, in 
addition to a block in TCR-mediated early activation events, 
such as Ca  2+  mobilization,  there is a more distal block as 
well. The deficiency in Ca  ~+ mobilization may be a gener- 
alizable  feature of anergic T  cells, since it has also been ob- 
served in unrelated  models of anergy (21,  22). 
The Human T Cells That Repopulate Chimeras Do Not Show 
Preferential TCR-V Gene Use.  While engrafting SCID mice 
with human PBL, we noted an initial rapid decline in human 
cells followed by their considerable expansion in the adop- 
tive host (Fig.  3). This dynamic is consistent with selection 
of lymphocyte subpopulations in the new environment. De- 
pendent on the nature of the selection process, the "successful" 
T  cell population may include a wide variety of clones, or 
only a few clones may establish themselves,  similar  to the 
oligoclonal repopulation of hu-PBL-SCID mice with human 
B cells (23). To study the T cell repertoire in hu-PBL-SCID 
chimeras, we defined the frequency of TCR-V gene positive 
T cells in the PBL population at grafting and we compared 
it with that in long-term chimeras. Using a panel of TCK-V 
gene-specific antibodies we found that the overall represen- 
tation  of T  cells expressing a particular  V  gene was com- 
parable in both populations (Table 2). Additionally, we hemi- 
splenectomized chimeras to compare the frequency of TCR 
V gene positive T  cells in a single chimera at two different 
time points.  Although  some shifts in the representation  of 
V gene + populations occurred with time in individual mice, 
the polyclonal nature of their T  cell repertoire was retained 
(Table 2).  These data show that  (a) the human T  cells that 
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Figure 2.  CD3 stimulation, as opposed to ionomycin 
treatment, does not induce Ca  2 + flux in freshly isolated 
chimera-derived human T  cells. (A) Subject's fresh PBL, 
(C) T  cells freshly isolated from a chimera, and (E) a T 
cell line derived from the same chimera after 59 d in cul- 
ture were challenged with anti-CD3 mAb (1 #g/ml) or 
ionomycin (2 mM), as indicated. The time point of stim- 
ulation is marked (A). The results are representative for 
six chimera-derived T  cell lines that originated from three 
different donors.  Normal Ca  2+  flux by PBL to CD3 or 
ionomycin  stimulation  are  shown in panels A  and B. 
Human  T  cells fresh from  the chimera failed to  show 
Ca  2+  flux  to  CD3  stimulation  (C)  while  these  cells 
showed Ca  2+  flux  to ionomycin  (D).  On  day  59,  the 
chimera-derived T  cell line first  showed Ca  z+  flux (E) 
and, also, a proliferative response to CD3 stimulation (data 
not shown). In the cell line younger than 52 d, no prolifer- 
ative response was induced and results identical to C and 
D  were obtained (data not shown). Ca  2+ flux was mea- 
sured in CD45 stained and gated cells (see Materials and 
Methods).  Thereby,  Ca  2§  flux  was  measured  only  in 
human cells which is pertinent to C and D where a mixed 
population of murine and human T cells were tested (57% 
H-2K d+ , 43% CD45 +CD3 +; of the human T  cells 22% 
were CD4 +  and 78%  were CDS+). 
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Figure 3.  Kinetics of SCID mouse population by human T cells. Mice 
were injected with 2  x  107 PBL i.p. and, at the indicated time points 
after grafting, mice were killed and the number of human cells (CD45 +  ) 
was assessed by flow cytometry analysis in cell suspensions obtained from 
the peritoneal cavity, lungs, liver, thymus, and the spleen. The cumulative 
cell numbers recovered from these organs of individual mice were used 
to establish the mean (solid line) and 1 SD (dotted lines) for each time point. 
Data obtained from 50 chimeras that have been grafted with either of 10 
human donors are shown: each data point was calculated  from 3-11 chimeras. 
The human cells were <98% T cells (5). During approximately the first 
20 d, human cells were detected in the peritoneal cavity only, where they 
persisted in low numbers (<2  x  106 cells). Around day 30, human cells 
appeared in lungs, liver, and spleen (5) where the vast majority of the human 
cells resided; human T cells occurred in lower numbers also in other organs 
of the chimeras (5), which we did not collect here. Therefore, the data 
accurately reflect the kinetics of repopulation but underrepresent the total 
number of human cells in the chimeras. 
populate the mice express a wide array ofT cell receptor genes, 
i.e.,  they are not mono- or oligoclonal;  and (b) there is no 
strong  selection for or against  the TCR V  genes tested. 
Chimera-derived T Cell Lines Show No Reactivity  for Recall 
Antigens.  We also assessed the human T  cell repertoire in 
hu-PBL-SCID mice using functional criteria,  asking whether 
clonally expanded T cell specificities  in the donor inoculum 
are also present  in high  numbers in the chimeras.  For ex- 
ample, if the donor was immunized  against tetanus toxoid 
and his  PBL were reactive to it, would T  cells specific for 
this recall antigen also be detectable in chimeras grafted with 
this donor's  PBL? 
Direct, functional assessment of the human T  cell reper- 
toire in the chimeras was impossible because of the anergic 
state by the chimera-derived  T  cells.  We therefore studied 
the antigen responsiveness  of chimera-derived T cell lines that 
had recovered from the anergic state after 1-2 mo of in vitro 
culture. When tested with T-depleted APC, none of these 
T  cell lines responded to the recall antigens  to which the 
donor's PBL responded (Table 3). Instead,  we noted that anti- 
SCID mouse reactivity,  which in PBL was comparable in 
magnitude to recall antigen responses (but much weaker than 
an alloresponse), prevailed in all chimera-derived T cell lines 
that  contained  >3%  CD4 §  cells  (39  of 42 T  cell lines). 
Only three T  cell lines,  which consisted of >97%  CD8 § 
cells, failed to proliferate in the presence of SCID stimulator 
cells, although these cell lines proliferated to CD3 stimula- 
tion  (Table 3). 
Table  2.  Expression of TCR-V Genes by Chimera-derived Human  T  Cells Is  Unbiased 
CD3 §  cells expressing V  gene 
Donor C 
Donor A  Donor B 
PBL  Chimera  PBL  Chimera  PBL 
TCR-V 
genes  day 0  day 56  day 0  day  106  day 0 
Chimera M1  and M2 
day 83  day  119 
M1  M2  M1  M2 
% 
~VS(a)  1.7  4.6  2.5  0.3  2.4  2.6  2.2  0.7  2.5 
flVS(b)  0.8  0.9  1.0  0.3  0.6  3.6  1.9  0.0  2.6 
~V5(c)  4.6  6.0  4.0  0.6  3.7  1.5  2.2  2.0  0.5 
~V6(a)  2.0  1.4  2.8  1.1  2.5  2.7  1.9  1.1  1.6 
~V8(a)  2.9  3.3  4.2  0.2  3.8  6.8  6.4  1.9  1.8 
BV12(a)  1.6  3.4  1.4  1.2  0.8  7.3  5.0  2.8  2.6 
oeV2(a)  3.0  2.0  2.3  1.1  2.8  5.7  6.6  0.5  0.6 
PBL of three human donors were stained with anti-CD3 mAb and with the listed mAbs specific  for TCK-V gene products. Two-color flow cytomet- 
ric analysis was performed to define the frequency of CD3 + cells  that express a particular V gene. On the same day (day 0) SCID mice were grafted 
with the PBL of these donors.  At the indicated time points, the frequency of CD3 +, TCK-V gene + cells was redefined in the spleens of chimeras. 
From two chimeras M1 and M2, (grafted by donor C) one half of their spleen was surgically removed on day 83. On day 119 these chimeras were 
killed and the other half of the spleen was recovered.  Flow cytometry was performed  at both time points. 
1822  CD4 + T  Cell Repertoire  in hu-PBL-SCID Table  3.  Unlike the Donors' PBL, Long-term CD4 § Chimera-derived Human  T  Cell Lines Do Not Respond to Recall Antigens But 
Proliferate to SCID Stimulator Cells 
Donor A  Donor B  Donor C 
CDHT*  CDHT* 
Proliferation to (cpm):  PBL  (64% CD4 §  PBL  (84% CD4 §  PBL 
CDHT* 
(99% CD8 § 
Medium  5,355  10,871  2,099  1,771  3,959  1,406 
TT  14,799  13,054  11,587  1,443  13,054  3,344 
PPD  31,796  8,146  31,075  2,440  6,234  666 
SCID  13,160  63,224  22,623  218,545  6,875  3,702 
otCD3  97,819  75,872  O.G)  174,198  125,323  170,441 
Underlined SI >3. 
* Long-term chimera-derived human T cell lines, tested with autologous irradiated T dep. PBL. 
Overgrown. 
The three CD8 + chimera-derived T cell lines did not ex- 
hibit cognate lyric activity against H-2  a target cells, but they 
were cytolytic  when their TCR was linked to the target cells 
with PHA (Fig. 4). Therefore, the lyric machinery was func- 
tional in these CD8 + cell lines, but, apparently, they were 
not specific for murine antigens expressed by the target cells. 
While these data are not sufficient to provide conclusions 
about the CD8 § T cell repertoire  in chimeras, they do dem- 
onstrate considerable positive and negative selection at the 
CD4 +  cell  level.  Since proliferative  responses  to  antigens 
provide a measure of the frequency of antigen-specific CD4 + 
T cells, our data show that during chimerism, and/or in vitro 
culture, the frequency of CD4 + T  cells specific for murine 
antigens increases considerably whereas the frequency of re- 
call antigen-specific  CD4 + cells decreases beyond the limit 
of detection (cloning of these T cell lines confirmed this no- 
tion, see below). 
Characterization  of CD4 + Chimera-derived  T  Cell Clones. 
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Figure  4.  Chimera-derived 
CD8 § human T cell lines are 
noncytolytic to  CB.17 Con A 
blasts, but kill these blasts in the 
presence of PHA. Three  chimera- 
derived T cell lines (11, 0, A) 
that were CD8 § and regained 
proliferative responsiveness  to 
CD3 stimulation  were tested in 
a standard 4-h 51Cr release assay 
(see Materials  and Methods). Cy- 
totoxicity  was tested  against  CB.17 
Con A blasts (H-2  d, congenic  to 
SCID)  in  the  absence (open 
symbols) or presence of 3 #g/ml 
PHA (solid  symbols). Similar  results 
were obtained using H.2Lex - 
pressing tumor cells J774 and A20 as target cells and chimera-derived 
CD8 § clones as effector  cells (not shown). The data are representative 
for two experiments performed. 
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We cloned chimera-derived T cell lines to establish  the fre- 
quency of anti-SCID mouse-specific clones among them. If 
xenoreactivity was  the  driving  force  for  engraftment  of 
CD4 +  human T  cells,  then all  (or  most)  clones isolated 
from chimera-derived T  cell lines should display anti-SCID 
specificity.  Alternatively, xenoantigen-driven repopulation 
would be unlikely if these cell lines contained only a minor 
fraction of xenoreactive T cells (which could still be sufficient 
to account for the anti-SCID reactivity of the lines). 
We cloned two cell lines in which the possibility of in vitro 
priming by murine ceils was minimalized; one line was es- 
tablished with added anti-CD3 mAb, the other cell line had 
murine cells removed by cell sorting before initiation of the 
culture. The cell lines originated from different human donors. 
Of 58 and 45 CD4 + T cell clones obtained, respectively, 46 
and 29 clones were responsive to CD3 stimulation. All these 
clones displayed anti-SCID mouse reactivity (Table 4).  The 
remaining clones were refractory to stimulation with anti- 
CD3 mAb or with SCID spleen  stimulator ceils, possibly 
due to persisting anergy or to chromosomal aberrations due 
to the chronic stimulation in the secondary host. Hence, every 
functional CD4 + T  cell  clone we isolated displayed  anti- 
SCID mouse reactivity. 
With respect  to fine  specificity,  these CD4 + clones fell 
into  two  major  categories.  The  majority of clones  were 
monospecific for H-2  d (expressed by both SCID and BALB/c 
stimulator cells) and did not respond to congenic stimulator 
cells that differed in the H-2 haplotype (BALB/k:H-2  k or 
BALB/b:H-2S).  Of the 29 and 46 functional T  cell clones 
obtained from the two donors, respectively,  22 and 36 ex- 
hibited this type of reactivity (sum of anti-I-A  a- or anti-I- 
Ed-specific clones in Table 4). These clones recognized poly- 
morphic H-2d  gene products, being specific for either the 
I-A  a or I-E  a molecule. Specificity  for I-E  a was defined by 
responsiveness  to B10.D2  stimulator ceils (I-A a,  I-E  a)  and 
failure to respond to congenic B10.GD stimulator cells (I-A d, 
I-E(b)) that do not express  an I-E molecule (Table 4).  Spe- 
cificity for I-A  a was defined by responsiveness  to B10.GD stimulator cells that was blocked by anti-I-Ad-specific mAb 
(Table 4). 
17 of the CD4 § clones, that displayed reactivity to H-2  d, 
also displayed reactivity to BALB/k (1-1-2  k) and/or BALB/b 
(H-2  b) stimulator cells (Table 4). As before, this response was 
either I-A- or I-E-restricted, as defined by antibody blocking 
experiments. Unlike the first set of clones that were mono- 
specific  for H-2 d products,  the latter  clones also crossreac- 
tively recognized other  allelic  MHC products,  in addition 
to H-2  d. 
The  finding  that  the  xenoresponse  of these  clones was 
blocked by antibodies specific for murine MHC products and, 
furthermore,  that  this response occurred in the absence of 
added human APC, suggests that the clones directly recog- 
nized native H-2 antigens on murine stimulator cells. How- 
ever, the specificity oft  cell clones obtained from T cell lines 
may not fully characterize the xenoreactivity by CD4 + cells 
in the chimeras.  Thus,  in several of our chimera-derived T 
cell lines the anti-SCID proliferative response was significantly 
increased in the presence of autologous, human, T cell-depleted 
APC  (not  shown).  This  finding  may  simply  result  from 
costimulation by human  accessory molecules or cytokines, 
but it may also reflect the occurrence of HLA restricted rec- 
ognition  of processed  murine  antigens  in  hu-PBL-SCID 
chimeras. 
Characterization  of CD8 + Chimera-derived  T  Cell  Clones. 
We obtained nine CD8 + T cell clones.  These clones prolifer- 
ated to anti-CD3  mAb in the presence of autologous APC 
but did not undergo blastogenesis when challenged with SCID 
stimulator  cells  (not  shown).  We tested the CD8 § clones 
in a standard  51Cr release  assays for cytotoxicity to the fol- 
lowing target cells:  (a)  CB.17 Con A blasts;  (b) A20 cells; 
Table  4.  Chimera-derived CD4 + Human  T  Cell  Clones Are 
Specific for Murine  MHC  Class II Products 1-.4 or I-E 
Name of clone  A9A12  A6C10  641C2 
Clone's  proliferation  to (cpm) 
Medium  773  2,542  254 
SCID (/-/-2  a)  11,709  699,692  238,425 
BALB/c (H-2  d)  44,473  372,280  85,604 
BALB/k(H-2 ~)  650  2,585  61,609 
BALB/b(H-2 ~)  768  ND  ND 
B10.GD(I-A d, I-E  b)  21,555"  1,545  83,624* 
BIO.D2(I-A d, I-E  d)  ND  197,835  83,142" 
Specificity  od.Ad*  ai_E d  o~l_A  d, ks 
No. of clones of this  type 
Donor  1:  21  1  7 
Donor 2:  27  9  10 
sI >3, underlined. 
* Inhibited by anti-I-A  d mAb (MK-D6). 
and (c) J774 cells. Although all these target cells shared the 
1-1-2  d  haplotype  with  SCID  mice  and  were  sensitive  to 
CD8 +-mediated cytotoxicity, we observed no or only mar- 
ginal lytic activity. However, all clones were cytolytic in the 
presence of PHA that mimicks antigen recognition (data not 
shown,  results  are identical  to  those obtained  testing  the 
CD8 § T  cell lines in Fig.  4).  Thus the CD8 + clones, like 
the three independent  CD8 + chimera-derived  T  cell lines, 
were functional  but  provided no  direct  evidence for anti- 
H-2d-specificity. 
In Vivo vs. In  Vitro Selection  of Xenoreactive  T  Cells.  Two 
lines of evidence provided in this report show that the human 
lymphocytes present  in long-term  hu-PBL-SCID chimeras 
do not constitute a functional human immune system in the re- 
cipient mice. First, all the human T cells, CD4 § and CD8 § 
T cells alike, are in a state of anergy upon their isolation from 
the chimeras.  Thus,  their proliferative phenotype (Fig.  1), 
their  deficiency in  lymphokine  production  (Table  1),  and 
Ca  2+  mobilization  (Fig.  2) are all features characteristic of 
anergic T cells (19). Second, our data strongly suggest that 
the  human  CD4 §  T  cell  repertoire  in  chimeras  is  being 
selected  for  and  confined  to  anti-SCID  mouse  reactive 
(xenoreactive)  specificities  (Table 3  and 4). 
Our  conclusion  that  xenoreactivity  is  the  stimulus  for 
shaping the CD4 § repertoire is based on indirect evidence, 
i.e., studies involving chimera-derived T cell lines and clones 
that have recovered from their state of anergy during long- 
term tissue culture in the presence of IL-2 (24,  25). How- 
ever,  six independent  lines of inferential  evidence all point 
to the same conclusion, that the selection of xenoreactive T 
cell  specificities  occurred in vivo. 
First,  selection of SCID mouse-specific T  cells in vitro, 
owing to the presence of murine cells in the culture, would 
require a TCR-dependent process. However, signaling through 
the  TCR  is uncoupled  in  chimera-derived  human  T  cells 
during  the first month  in culture (Fig.  2), by which time 
murine cell contaminants have been lost from the cell lines. 
The frequency of H-2K  a+ murine cells drops beyond the de- 
tection limit by FACS  |  analysis within the first 14 d of cul- 
ture  (Tary-Lehmann,  M.,  unpublished  observation). 
Second, the anergic,  chimera-derived T  cell lines,  which 
we tested repeatedly for responsiveness to CD3 stimulation 
and SCID mouse reactivity,  simultaneously acquired a prolifer- 
ative responsiveness  to both stimuli. Importantly, this earliest 
response is comparable in magnitude to both stimuli,  sug- 
gesting that  the frequency of SCID mouse reactive T  cells 
in  these  cell  lines  closely matches  the  frequency  of anti- 
CD3-reactive CD4 § cells, even at the time point when the 
T  cells have just regained reactivity (Table 3). This finding 
argues against a gradual selection process due to undetectably 
rare contaminating murine cells after the human T cells have 
recovered from their  anergic  state. 
Third,  to  "mimic"  a TCR-related  selection process, we 
added anti-CD3 mAb to freshly isolated cells, and obtained 
SCID mouse-reactive CD4 + lines as well.  The same reac- 
tivity was displayed by T cell lines that have been established 
after removal ofmurine cells by FACS  |  sorting. In fact, within 
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we have isolated was anti-SCID  mouse reactive (Table 4). 
Fourth,  the fact that, in the chimeras,  the human T cells 
uniformly express an activated/memory phenotype (CD45 
R0 +,  HLA-DR +)  (5,  6,  9-11)  also favors  the notion of a 
(xeno-) antigen-driven process. Activated/memory cells are 
short lived in the absence of their cognate antigen (26). Thus, 
it is likely that only those memory cell specificities  establish 
themselves in themice that are stimulated by (xeno-) antigen 
recognition (Table 3). If repopulation was independent of an- 
tigen recognition,  one would expect that long-lived T  cell 
populations would persist in the mice, as they are thought 
to be naive/resting cells (27).  For reasons that  are unclear, 
phenotypically naive (CD45RA +,  HLA-DR-)  T  cells  do 
not persist in SCID mice. To the contrary, injection of cord 
blood that contains only T cells of the naive phenotype, results 
in phenotype conversion and repopulation by T cells that ex- 
press  activation/memory  markers  (5).  This,  too,  strongly 
argues for a (xeno-)  antigen-driven  process. 
Fifth, the anergic state of the human T cells in the chimeras 
is indicative of a (xeno-) antigen-driven engraftment. All pre- 
viously defined mechanisms that lead to T cell anergy result 
from antigen  recognition  (19,  28-31).  Since  the transition 
of the human T  cells from a functional to an anergic state 
occurs during chimerism  (Fig.  2), it has to be mediated by 
antigens that the human T cells encounter in the mouse. The 
specificity of the chimera-derived T cell clones suggests that, 
in the case of CD4 + cells, native murine MHC products are 
being recognized directly on the murine cells (Table 4). Ap- 
parently, this xenoantigen recognition on murine cells results 
in induction  of anergy in  the human  T  cells. 
Finally,  we can not envision a scenario in which human 
T  cells that  are highly responsive to SCID MHC-products 
in vitro (Tables  3  and 4) would persist,  unaffected,  in the 
chimeras  for  weeks.  We  conclude  that  the  xenoantigen 
specificity of the long-term,  chimera-derived CD4 + T  cell 
lines and clones fully characterizes  the CD4 + repertoire in 
hu-PBL-SCID mice. Our data suggest that graft-vs.-host re- 
activity is the driving force for the population of SCID mice 
by human  CD4 + cells. 
Our data on the human CD8 + cell compartment  in the 
chimeras are more complex. On one hand, long-term chimera- 
derived human  CD8 §  T  cell lines  and clones did not dis- 
play detectable anti-H-2 d reactivity (Fig.  4).  On the other 
hand,  the human  CD8 + cells uniformly displayed an acti- 
vated phenotype in the mice (5) and these lymphocytes also 
developed a long lasting  anergy  during  chimerism,  being 
deficient  in Ca  2+ mobilization (Fig.  2), lymphokine produc- 
tion  (Table  1),  and blastogenesis (Fig.  1).  That  the CD8 + 
cells have been rendered anergic in the chimera is highly sug- 
gestive for antigen recognition (22) implying a (xeno-) antigen- 
driven process. In spite of the absence of a detectable reac- 
tivity to  SCID  spleen cells (Table  3) and H-2a-expressing 
cell lines (Fig. 4), the chimera-derived CD8 + cells could be 
specific for murine  antigens  that  are expressed in  a tissue- 
specific manner and presented in association with murine class 
I molecules in organs other than the spleen.  It is also pos- 
sible that,  in the chimeras,  human CD8 + cells are selected 
that have low affinity for murine antigens: a low affinity TCR 
signal is known to partially activate T  cells rendering them 
unresponsive to subsequent, optimal stimulation (28). There- 
fore, the activated, anergic state of these cells in the chimeras 
may suggest a xenoantigen-driven  repopulation by human 
CD8 § cells. 
Conclusions on hu-PBL-SCID Chimeras.  The anergy that 
we observe in the xenoantigen reactive, chimera-derived  human 
T  cells may be a consequence of deficient costimulation in 
the murine environment.  Reminiscent of the T cell response 
to superantigens (32-34), in which costimulation is thought 
to be deficient, an initial extensive clonal expansion is trig- 
gered,  followed by contraction  of clonal  sizes  and anergy. 
However, initial expansion followed by contraction of clonal 
sizes and anergy has also been reported for mature, HY an- 
tigen-specific  murine  CD8 + cells  that  were injected  into 
HY expressing hosts (35). Therefore, anergy may be the out- 
come of a "frustrated" T cell response where the antigen can 
not be cleared and continued T  cell stimulation  results,  as 
it is the case for anti-mouse-specific human T  cells in hu- 
PBL-SCID chimeras. We have found that the human T cells 
are already anergic 4-6 wk after grafting (5), at which time 
the T  cell pool expands in chimeras  (Fig.  3) and at which 
time strong mitotic activity is seen by cell cycle analysis  (5, 
6). Therefore, the antigen recognition event that induces the 
anergic state in the T cell appears to be followed by extensive 
proliferation, i.e., induction of anergy precedes proliferation. 
At the peak of chimerism, -1 mo after grafting, the numbers 
of T  cells recovered from organs of the chimeras can exceed 
the number injected by 10-fold (Fig.  3). The subsequent de- 
cline in numbers of human T  cells in the chimera (Fig.  3) 
may correspond to the contraction of clonal sizes that is seen 
with the superantigen (32-34) and HY antigen (35) response. 
The early transition of the xenoreactive human T cells from 
a functional to an anergic state, before the extensive prolifer- 
ation by the lymphocytes, explains why overt symptoms of 
GVHD fail to develop in chimeras whose organs can contain 
up to 80%  (xenoreactive) human  T  cells  (5).  However, it 
should be noted that mild symptoms of GVHD, possibly medi- 
ated by the first generation of still functional T cells, are not 
uncommon in chimeras.  These include splenomegaly (9), fol- 
lowed by atrophy of the spleen (6), and spontaneous autoan- 
tibody production to red blood cells (36),  all characteristic 
features of GVHD. 
In summary, our data imply that hu-PBL-SCID chimerism 
represents  a novel type of graft-vs.-host reactivity that is atyp- 
ical due to the early development of anergy in the effector 
cells. Apparently,  the hu-PBL-SCID  model does not fulfill 
the promise to provide a functional human immune system 
in an experimental animal. However, this model contributes 
a powerful model for experimentation on human T lympho- 
cytes in vivo if an immunocompetent  T  cell system is not 
a requirement,  e.g., for the infection of human T cells with 
HIV (37).  Also, it provides a unique model for studies of 
anergy in vivo. Future attempts  to improve the model to- 
wards constructing a functional human immune  system in 
1825  Tary-Lehmann  et al. the mouse will have to overcome at least three of its deficien- 
cies:  the lack of human  accessory cells in lymphoid organs 
of the chimeras to serve as APC; the induction of an antihost 
response;  and  the decay of non-xenoreactive T  cells. 
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